Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics, has announced the completion of a US$25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital. Latham […]
The post Latham & Watkins Advises Codagenix in US$25 Million Series B Extension Financing appeared first on Legal Desire.